ECSP088136A - Derivados de ciclohexilaminisoquinolona en calidad de inhibidores de rho-quinasa - Google Patents

Derivados de ciclohexilaminisoquinolona en calidad de inhibidores de rho-quinasa

Info

Publication number
ECSP088136A
ECSP088136A EC2008008136A ECSP088136A ECSP088136A EC SP088136 A ECSP088136 A EC SP088136A EC 2008008136 A EC2008008136 A EC 2008008136A EC SP088136 A ECSP088136 A EC SP088136A EC SP088136 A ECSP088136 A EC SP088136A
Authority
EC
Ecuador
Prior art keywords
rho
derivatives
cyclhexylaminisoquinolone
quinasa
inhibitors
Prior art date
Application number
EC2008008136A
Other languages
English (en)
Inventor
Armin Hofmeister
Oliver Plettenburg
Dieter Kadereit
Joachim Brendel
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ECSP088136A publication Critical patent/ECSP088136A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)

Abstract

La invención se refiere a derivados de isoquinolona sustituidos con 6-ciclohexilamina de fórmula (I) (I),o a derivados de isoquinolina de la fórmula (I') (I')útiles para el tratamiento y/o prevención de enfermedades asociadas con la Rho-quinasa y/o la fosforilación mediada por la Rho-quinasa de la fosfatasa de la cadena ligera de miosina, y a composiciones que contienen tales compuestos.
EC2008008136A 2005-07-26 2008-01-25 Derivados de ciclohexilaminisoquinolona en calidad de inhibidores de rho-quinasa ECSP088136A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05016153 2005-07-26

Publications (1)

Publication Number Publication Date
ECSP088136A true ECSP088136A (es) 2008-02-20

Family

ID=35115842

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008136A ECSP088136A (es) 2005-07-26 2008-01-25 Derivados de ciclohexilaminisoquinolona en calidad de inhibidores de rho-quinasa

Country Status (37)

Country Link
US (2) US8609691B2 (es)
EP (1) EP1912949B1 (es)
JP (1) JP5049970B2 (es)
KR (1) KR101336678B1 (es)
CN (1) CN101228132B (es)
AR (1) AR057082A1 (es)
AT (1) ATE521595T1 (es)
AU (1) AU2006274246B2 (es)
BR (1) BRPI0614063A2 (es)
CA (1) CA2615663C (es)
CR (1) CR9604A (es)
CY (1) CY1112085T1 (es)
DK (1) DK1912949T3 (es)
DO (1) DOP2006000177A (es)
EC (1) ECSP088136A (es)
ES (1) ES2372067T3 (es)
GT (1) GT200600327A (es)
HK (1) HK1123036A1 (es)
HN (1) HN2008000130A (es)
HR (1) HRP20110839T1 (es)
IL (1) IL188949A (es)
MA (1) MA29639B1 (es)
MX (1) MX2008000956A (es)
MY (1) MY146644A (es)
NI (1) NI200800024A (es)
NO (1) NO20080965L (es)
NZ (1) NZ565669A (es)
PE (1) PE20070181A1 (es)
PL (1) PL1912949T3 (es)
PT (1) PT1912949E (es)
RS (1) RS52241B (es)
RU (1) RU2440988C2 (es)
SI (1) SI1912949T1 (es)
TN (1) TNSN08038A1 (es)
TW (1) TWI412521B (es)
WO (1) WO2007012422A1 (es)
ZA (1) ZA200710952B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1899322E (pt) 2005-06-28 2009-11-09 Sanofi Aventis Derivados de isoquinolina como inibidores de rho-cinase
NI200800025A (es) 2005-07-26 2009-03-03 Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa
ATE521595T1 (de) 2005-07-26 2011-09-15 Sanofi Sa Cyclohexylaminisochinolonderivate als rho-kinase- inhibitor
US7893088B2 (en) * 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
ATE523493T1 (de) * 2006-09-11 2011-09-15 Organon Nv 2-(1-oxo-1h-isochinolin-2-yl) acetamid-derivate
CA2673920C (en) * 2006-12-27 2015-03-24 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
AU2007338408B2 (en) 2006-12-27 2012-07-26 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
MX2009005825A (es) 2006-12-27 2009-06-16 Sanofi Aventis Derivados de isoquinolina e isoquinolinona sustituidos en calidad de inhibidores de rho-quinasa.
JP5405314B2 (ja) * 2006-12-27 2014-02-05 サノフイ シクロアルキルアミン置換イソキノロン誘導体
CN101573354B (zh) 2006-12-27 2014-02-12 塞诺菲-安万特股份有限公司 取代的异喹啉类及其作为Rho-激酶抑制剂的用途
SI2102164T1 (sl) 2006-12-27 2011-03-31 Sanofi Aventis Izokinolinski in izokinolinonski derivati, substituirani s cikloalkilaminom
CL2008000973A1 (es) 2007-04-05 2009-01-02 Astrazeneca Ab Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma.
JP5524071B2 (ja) * 2007-10-24 2014-06-18 メルク・シャープ・アンド・ドーム・コーポレーション 複素環フェニルアミドｔ型カルシウムチャネルアンタゴニスト
MX2010013974A (es) * 2008-06-24 2011-01-14 Sanofi Aventis Isoquinolinas e isoquinolinonas 6-sustituidas.
RU2538588C2 (ru) * 2008-06-24 2015-01-10 Санофи-Авентис ЗАМЕЩЕННЫЕ ИЗИХИНОЛИНЫ И ИЗОХИНОЛИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
DK2303845T3 (da) * 2008-06-24 2013-12-16 Sanofi Sa Bi- og polycyklisk substitueret isoquinolin og bi- og polycykliske substituerede isoquinolinderivater som rho-kinasehæmmere
KR101354763B1 (ko) 2008-08-25 2014-01-22 아이알엠 엘엘씨 헷지호그 경로 조절제
AR073711A1 (es) 2008-10-01 2010-11-24 Astrazeneca Ab Derivados de isoquinolina
EP3252050B1 (en) * 2013-01-18 2020-02-26 Bristol-Myers Squibb Company Phthalazinones and isoquinolinones as rock inhibitors
CA2927567C (en) 2013-10-18 2022-04-26 Celgene Quanticel Research, Inc. Bromodomain inhibitors
WO2015060373A1 (ja) * 2013-10-23 2015-04-30 中外製薬株式会社 キナゾリノンおよびイソキノリノン誘導体
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN105085478B (zh) * 2014-04-28 2019-04-12 南京明德新药研发股份有限公司 异喹啉磺胺衍生物及其药物组合物和制药用途
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
EP3294871A1 (en) 2015-05-12 2018-03-21 Platod Combination of pharmacological and microfluidic features for improved platelets production
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
JP2019513804A (ja) 2016-04-18 2019-05-30 セルジーン クオンティセル リサーチ，インク． 治療用化合物
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
CA3102645A1 (en) * 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
CN114874236B (zh) * 2022-06-24 2023-05-05 中国工程物理研究院化工材料研究所 一种五元氮杂稠环骨架及其制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485537B2 (fr) 1977-04-13 1986-05-16 Anvar Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
EP0541559A1 (en) 1990-07-31 1993-05-19 E.I. Du Pont De Nemours And Company Catalytic equilibration of selected halocarbons
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
SI0956865T2 (sl) 1996-08-12 2011-04-29 Mitsubishi Pharma Corp Zdravila, ki obsegajo inhibitor Rho-kinaze
JPH1087629A (ja) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd 新規イソキノリン誘導体、およびその医薬用途
EP1007525A1 (en) 1997-08-29 2000-06-14 Zeneca Limited Aminometyl oxooxazolidinyl benzene derivatives
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
US6541456B1 (en) 1999-12-01 2003-04-01 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
MXPA02007036A (es) 2000-01-20 2002-12-13 Eisai Co Ltd Compuesto de piperidina novedoso y composicion farmaceutica del mismo.
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AU2001239947A1 (en) 2000-02-29 2001-09-12 Curis, Inc. Methods and compositions for regulating adipocytes
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
AU2001296008A1 (en) 2000-10-27 2002-05-06 Takeda Chemical Industries Ltd. Process for preparing substituted aromatic compounds and intermediates therefor
WO2002055496A1 (en) 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
SE0101038D0 (sv) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
WO2002088101A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
JPWO2002100833A1 (ja) * 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
KR20050019918A (ko) * 2002-07-22 2005-03-03 아사히 가세이 파마 가부시키가이샤 5-치환 이소퀴놀린 유도체
JPWO2004009555A1 (ja) * 2002-07-22 2005-11-17 旭化成ファーマ株式会社 ５−置換イソキノリン誘導体
JPWO2004024717A1 (ja) 2002-09-12 2006-01-05 麒麟麦酒株式会社 キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬
PT1603566E (pt) * 2003-03-11 2009-04-27 Novartis Ag Utilização de derivados de isoquinolina para tratamento de cancro e de doenças relacionadas com map-cinase
US20040225116A1 (en) 2003-05-08 2004-11-11 Payne Mark S. Nucleic acid fragments encoding nitrile hydratase and amidase enzymes from comamonas testosteroni 5-MGAM-4D and recombinant organisms expressing those enzymes useful for the production of amides and acids
US20050014783A1 (en) 2003-05-29 2005-01-20 Schering Aktiengesellschaft Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
US20070021404A1 (en) 2003-06-24 2007-01-25 Dan Peters Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2005020081A2 (en) 2003-08-22 2005-03-03 4Links Limited Communication system using embedded synchronisation
US7691879B2 (en) 2003-09-23 2010-04-06 Merck Sharp & Dohme Corp. Isoquinoline potassium channel inhibitors
CN1856476A (zh) 2003-09-23 2006-11-01 默克公司 异喹啉酮钾通道抑制剂
US20050067037A1 (en) 2003-09-30 2005-03-31 Conocophillips Company Collapse resistant composite riser
EP1671962A1 (en) * 2003-10-10 2006-06-21 Ono Pharmaceutical Co., Ltd. Novel fused heterocyclic compound and use thereof
EP1689719A1 (en) 2003-11-25 2006-08-16 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
EP1729761A4 (en) 2004-03-05 2008-09-03 Eisai Co Ltd TREATMENT OF CADASIL WITH CHOLINESTERASE INHIBITORS
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
JP4969049B2 (ja) * 2004-04-06 2012-07-04 株式会社アマダ 曲げ加工装置
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
EP1741525A1 (de) 2005-07-06 2007-01-10 Trumpf Werkzeugmaschinen GmbH + Co. KG Vorrichtung zur Aufnahme von plattenförmigen Materialien
NI200800025A (es) 2005-07-26 2009-03-03 Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa
ATE521595T1 (de) 2005-07-26 2011-09-15 Sanofi Sa Cyclohexylaminisochinolonderivate als rho-kinase- inhibitor
TW200745101A (en) 2005-09-30 2007-12-16 Organon Nv 9-Azabicyclo[3.3.1]nonane derivatives
JP4033221B2 (ja) 2005-12-02 2008-01-16 ダイキン工業株式会社 冷媒加熱装置
US7618985B2 (en) 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
TW200738682A (en) 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7893088B2 (en) 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
CN101573354B (zh) 2006-12-27 2014-02-12 塞诺菲-安万特股份有限公司 取代的异喹啉类及其作为Rho-激酶抑制剂的用途
SI2102164T1 (sl) 2006-12-27 2011-03-31 Sanofi Aventis Izokinolinski in izokinolinonski derivati, substituirani s cikloalkilaminom

Also Published As

Publication number Publication date
DK1912949T3 (da) 2011-11-28
PT1912949E (pt) 2011-11-23
DOP2006000177A (es) 2007-06-15
TW200800906A (en) 2008-01-01
WO2007012422A1 (en) 2007-02-01
SI1912949T1 (sl) 2011-12-30
RU2440988C2 (ru) 2012-01-27
TWI412521B (zh) 2013-10-21
EP1912949B1 (en) 2011-08-24
IL188949A0 (en) 2008-04-13
AR057082A1 (es) 2007-11-14
IL188949A (en) 2013-11-28
PE20070181A1 (es) 2007-03-07
HK1123036A1 (en) 2009-06-05
ATE521595T1 (de) 2011-09-15
HRP20110839T1 (hr) 2011-12-31
MX2008000956A (es) 2008-03-27
KR101336678B1 (ko) 2013-12-04
HN2008000130A (es) 2010-12-27
GT200600327A (es) 2007-02-05
NO20080965L (no) 2008-02-22
AU2006274246B2 (en) 2012-07-12
CY1112085T1 (el) 2015-11-04
CA2615663C (en) 2013-10-15
MA29639B1 (fr) 2008-07-01
US8796458B2 (en) 2014-08-05
CN101228132A (zh) 2008-07-23
JP5049970B2 (ja) 2012-10-17
CA2615663A1 (en) 2007-02-01
CN101228132B (zh) 2012-10-10
EP1912949A1 (en) 2008-04-23
NI200800024A (es) 2009-03-03
JP2009502830A (ja) 2009-01-29
CR9604A (es) 2008-04-10
TNSN08038A1 (en) 2009-07-14
BRPI0614063A2 (pt) 2011-03-09
US20110251226A1 (en) 2011-10-13
US8609691B2 (en) 2013-12-17
RU2008106926A (ru) 2009-09-10
PL1912949T3 (pl) 2012-01-31
ES2372067T3 (es) 2012-01-13
NZ565669A (en) 2010-05-28
AU2006274246A1 (en) 2007-02-01
ZA200710952B (en) 2008-11-26
US20080242699A1 (en) 2008-10-02
KR20080028970A (ko) 2008-04-02
MY146644A (en) 2012-09-14
RS52241B (en) 2012-10-31

Similar Documents

Publication Publication Date Title
ECSP088136A (es) Derivados de ciclohexilaminisoquinolona en calidad de inhibidores de rho-quinasa
NI200800025A (es) Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa
DOP2006000149A (es) Derivados de isoquinolina
ECSP099466A (es) Derivados de isoquinolina e isoquinolinona sustituidos en calidad de inhibidores de rho-quinasa
ECSP099467A (es) Derivados de isoquinolona sustituidos con cicloalquilamina
ECSP099469A (es) Nuevos derivados de isoquinolina e isoquinolinona sustituidos
ECSP099470A (es) Nuevos derivados de isoquinolina e isoquinolinona sustituidos
ECSP099468A (es) Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina
DOP2010000394A (es) Isoquinolas e isoquinolinonas sustituidas en calidad de inhibidores de la rho-quinasa
UY29698A1 (es) Derivados de ciclohexilaminisoquinolona
NO20080419L (no) Isokinolinderivater som inhibitorer av Rho-kinase
UY30841A1 (es) Nuevos derivados de isoquinolina e isoquinolinona sustituidos